Zhang W J, Wojta J, Binder B R
Department of Vascular Biology and Thrombosis Research, University of Vienna, Austria.
Cell Mol Biol (Noisy-le-grand). 1997 Jun;43(4):581-7.
We have previously reported that notoginsenoside R1 (NG-R1) increases the synthesis of tissue-type plasminogen activator (t-PA) and decreases plasminogen activator inhibitor-1 (PAI-1) activity in cultured human endothelial cells from different vascular sources. It was the aim of this study to investigate whether the effect of NG-R1 on the synthesis of components of the fibrinolytic system is also operative in another cell type of the blood vessel wall, the smooth muscle cell. Therefore cultured human pulmonary artery smooth muscle cells (HPASMCs) were treated with NG-R1. When the HPASMCs (passage 4 or 5) were conditioned with NG-R1, a dose (0.01-100 micrograms NG-R1/ml for 24 hrs.) dependent increase in t-PA an u-PA synthesis was observed, which was significant from 1 microgram NG-R1/ml on. t-PA antigen increased from 2.4 +/- 0.1 to 4.7 +/- 0.5 ng/10(5) cells/24 hrs.; u-PA antigen increased from 1.8 +/- 0.1 to 3.0 +/- 0.4 ng/10(5) cells/24 hrs. In contrast no change in PAI-1 antigen synthesis was seen in the conditioned media from NG-R1 treated HPASMCs. On Northern blot analysis of mRNA obtained from NG-R1-stimulated and control HPASMCs NG-R1 induced a significant increases in mRNA levels of t-PA and u-PA (180% and 200% of control value, respectively) at 100 micrograms NG-R1/ml while PAI-1 mRNA decreased slightly. In conclusion our data give evidence that NG-R1 can increase the fibrinolytic potential in cultured HPASMCs in vitro by increasing the production of t-PA and u-PA. If operative in vivo this effect of NG-R1 on the fibrinolytic system of SMCs might also contribute to the effect of the Chinese herb drug Panax notoginseng in the treatment of cardiovascular diseases.
我们之前曾报道,三七皂苷R1(NG-R1)可增加来自不同血管来源的培养人内皮细胞中组织型纤溶酶原激活物(t-PA)的合成,并降低纤溶酶原激活物抑制剂-1(PAI-1)的活性。本研究的目的是调查NG-R1对纤溶系统成分合成的影响在血管壁的另一种细胞类型——平滑肌细胞中是否也起作用。因此,用NG-R1处理培养的人肺动脉平滑肌细胞(HPASMCs)。当用NG-R1处理HPASMCs(第4或5代)时,观察到t-PA和尿激酶型纤溶酶原激活物(u-PA)合成呈剂量(0.01 - 100微克NG-R1/毫升,处理24小时)依赖性增加,从1微克NG-R1/毫升起具有显著性。t-PA抗原从2.4±0.1增加到4.7±0.5纳克/1细胞/24小时;u-PA抗原从1.8±0.1增加到3.0±0.4纳克/1细胞/24小时。相比之下,在NG-R1处理的HPASMCs条件培养基中,PAI-1抗原合成未见变化。对从NG-R1刺激的和对照HPASMCs获得的mRNA进行Northern印迹分析,在100微克NG-R1/毫升时,NG-R1诱导t-PA和u-PA的mRNA水平显著增加(分别为对照值的180%和200%),而PAI-1 mRNA略有下降。总之,我们的数据表明,NG-R1可通过增加t-PA和u-PA的产生来提高体外培养的HPASMCs中的纤溶潜力。如果在体内起作用,NG-R1对平滑肌细胞纤溶系统的这种作用可能也有助于中药三七在心血管疾病治疗中的效果。